Organon & Co. (BIT:1OGN)

Market Cap	2.17B
Revenue (ttm)	5.82B
Net Income (ttm)	693.90M
Shares Out	n/a
EPS (ttm)	2.66
PE Ratio	3.13
Forward PE	2.58
Dividend	0.80 (9.33%)
Ex-Dividend Date	May 9, 2025

Volume	n/a
Average Volume	23
Open	8.59
Previous Close	8.59
Day's Range	8.59 - 8.59
52-Week Range	7.03 - 21.47
Beta	n/a
RSI	55.49
Earnings Date	Aug 7, 2025

About Organon & Co.

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to...

• Industry: Pharmaceutical Preparations
• Founded: 1923
• Employees: 10,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1OGN

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD